Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ENOV
BUYFLAGEnovis Corporation · Healthcare · United States · $1.6B · Avg Vol: $32M/d
Enovis has value V67 and momentum M64 with a nominal insider buy, but quality at Q40 is below the calibrated floor, so stage one fails.
COMPANY DESCRIPTION
Enovis Corporation is a global medical technology company dedicated to advancing musculoskeletal care through its diverse portfolio of orthopedic rehabilitation, surgical, and preventative solutions. Its competitive advantage stems from a broad product range spanning joint reconstruction, bracing, and surgical technologies, supported by established distribution channels and a focus on innovation. Enovis maintains a significant presence in the orthopedic market, addressing patient needs from injury prevention to recovery.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.6B | 1.7B | 2.1B | 2.2B | 12.9% | 2.3B | 2.3B | 2.5B | 4.7% |
| EPS | -0.25 | -0.61 | -14.93 | -20.75 | — | -19.72 | — | — | — |
| Shares | 54.2M | 54.6M | 55.9M | 57.2M | +5.5% | 57.6M | — | — | — |
| Debt | 334.8M | 536.4M | 1.4B | 1.4B | 60.3% | 1.4B | — | — | — |
| Equity | 3.4B | 3.4B | 2.6B | 1.5B | -24.4% | — | — | — | — |
| Op CF | -55.9M | 135.0M | 113.5M | 217.3M | 26.9% | 242.8M | — | — | — |
| Inv CF | -176.4M | -242.5M | -955.5M | -179.4M | — | — | — | — | — |
| Fin CF | -465.1M | 127.8M | 846.8M | -52.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ENOV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ENOV | Enovis Corporation(you) | $1.6B | 80 | BUY |
| IART | Integra LifeSciences Holdings Corporation | $1.5B | 80 | BUY |
| AHCO | AdaptHealth Corp. | $1.5B | 79 | BUY |
| IRMD | IRADIMED CORPORATION | $1.2B | 78 | BUY |
| UFPT | UFP Technologies, Inc. | $1.8B | 75 | BUY |
| CNMD | CONMED Corporation | $1.3B | 86 | STRONG BUY |
| AVNS | Avanos Medical, Inc. | $1.2B | 72 | BUY |
| ITGR | Integer Holdings Corporation | $3.3B | 72 | BUY |
| AXGN | Axogen, Inc. | $2.1B | 62 | HOLD |
| HAE | Haemonetics Corporation | $3.6B | 89 | STRONG BUY |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%